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The landmark studies on therapeutic hypothermia have
demonstrated an improved outcome in comatose patients
after cardiac arrest targeting a temperature of 33°C for
24 hours [1,2]. The investigated temperature of 33°C was
derived from the results of animal studies suggesting the best
compromise between neuroprotection and adverse events.
In the decade that followed, no randomized controlled
trial of hypothermia was conducted. Thus, hypothesis-
generating data from clinical registries were used to direct
future investigations [3]. Surprisingly, data from a large
registry of almost 1,000 patients and other observational
studies were unable to demonstrate a benefit from the
actual depth of temperature achieved, as well as time to
hypothermia, time to target temperature, duration of
hypothermia and rate of rewarming. This sets the premises
and rationale of the Target Temperature Management
Trial that investigated two different temperature regimes:
33°C and 36°C [4]. The study demonstrated identical
long-term survival, 6 months neurological recovery and
rate adverse events between the two temperature groups.
This pragmatic trial enrolled a larger (939 patients) and
less selected population compared with previous rando-
mized studies. When looking at predefined subpopulations
again there was benefit of one regimen over the other. Yet
a numerical (nonstatistical) trend favors patients treated at
36°C. Most surprisingly, this nonstatistical advantage
seems to favor patients likely to be exposed to a more
severe injury, such as prolonged time from cardiac arrest
to return of spontaneous circulation (median >25 minutes)
or shock at admission (respectively HR 1.20 (95% CI 0.96
to 1.50) and HR 1.35 (95% CI 0.90 to 2.03)) [4]. Shock was
previously considered an exclusion criterion due to alleged
poor prognosis. In this subpopulation, arterial lactate
levels were significantly higher in the 33°C throughout
the intervention period of 36 hours ( P= 0.004) [5]. During
the first week of ICU, the extended cardiovascular SOFA
score – accounting also for need of vasopressors – was
again significantly higher in the 33°C group between days
2 and 4 [5].
Based on the evidence so far available, the most recent
Consensus on Science and Treatment Recommendations
(Dallas 2015) from the International Liaison Committee on
Resuscitation recommends selecting and maintaining a con-
stant target temperature between 32 and 34°C [6]. Whether
certain subpopulations of cardiac arrest may benefit from a
lower (32 to 34°C) or higher (36°C) temperature remains
unknown.
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